Human Epidermal growth factor Receptor type 2 (HER2) is over expressed in 20.0-30.0% of breast cancers and is currently evaluated histopathologically. Immunohistochemistry and fluorescence in situ hybridization require invasive enucleation of the tumor tissue and may be affected by heterogeneity. Serum marker tests are more objective because of the uniformity of the study material. Serum HER2 levels are important for breast cancer care. However, the clinical utility of serum HER2 testing is unclear. We evaluated serum HER2 as a marker of therapeutic response in breast cancer.
TY - JOUR. T1 - Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab. T2 - A multicenter retrospective observational study (JBCRG-C03 study). AU - Takada, M.. AU - Ishiguro, H.. AU - Nagai, S.. AU - Ohtani, S.. AU - Kawabata, H.. AU - Yanagita, Y.. AU - Hozumi, Y.. AU - Shimizu, C.. AU - Takao, S.. AU - Sato, N.. AU - Kosaka, Y.. AU - Sagara, Y.. AU - Iwata, H.. AU - Ohno, S.. AU - Kuroi, K.. AU - Masuda, N.. AU - Yamashiro, H.. AU - Sugimoto, M.. AU - Kondo, M.. AU - Naito, Yasuhiro. AU - Sasano, H.. AU - Inamoto, T.. AU - Morita, S.. AU - Toi, M.. PY - 2014. Y1 - 2014. N2 - We investigated the disease-free survival (DFS) of HER2-positive primary breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab, as well as predictive factors for DFS and pathologic response. Data from 829 female patients treated between 2001 and 2010 were collected from 38 institutions in Japan. Predictive factors were evaluated using ...
TY - JOUR. T1 - Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases. AU - Glück, Stefan. AU - Castrellon, Aurelio. PY - 2009/11/1. Y1 - 2009/11/1. N2 - Brain metastases affect 25%-30% of women with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer and are associated with a high burden of disease and poor prognosis. A 55-year-old woman presented with HER2-positive, hormone receptor-positive, locally advanced infiltrating ductal carcinoma. She received 4 cycles of neoadjuvant docetaxel (75 mg/m2) plus trastuzumab (6 mg/kg) on a 21-day cycle, resulting in complete pathologic response at the time of surgery. Trastuzumab (6 mg/kg every 21 days) plus anastrozole (1 mg/d) was continued for 1 year. Two years later, the patient progressed with pulmonary nodules and a large pleural effusion. Computed tomography and positron emission tomography revealed multiple lesions in the liver and thoracic spine but no evidence of ...
in Breast Cancer (2014), 6. Many systemic treatment options are available for advanced breast cancer, including endocrine therapy, chemotherapy, anti-human epidermal growth factor receptor 2 (HER2) therapy, and other targeted agents ... [more ▼]. Many systemic treatment options are available for advanced breast cancer, including endocrine therapy, chemotherapy, anti-human epidermal growth factor receptor 2 (HER2) therapy, and other targeted agents. Recently, everolimus, a mammalian target of rapamycin (mTOR) inhibitor, combined with exemestane, an aromatase inhibitor, has been approved in Europe and the USA for patients suffering from estrogen receptor-positive, HER2-negative advanced breast cancer previously treated by a nonsteroidal aromatase inhibitor, based on the results of BOLERO-2 (Breast cancer trials of OraL EveROlimus). This study showed a statistically significant and clinically meaningful improvement in median progression-free survival. Results concerning the impact on overall ...
Single-agent poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have been approved as the first targeted therapy available for patients with BRCA-mutated HER2-negative metastatic breast cancer. This meta-analysis aimed to better evaluate activity, efficacy and safety of single-agent PARPi in this population. A systematic search of Medline, Embase and conference proceedings up to 31 January 2018 was conducted to identify randomised controlled trials (RCTs) investigating single-agent PARPi versus monochemotherapy in patients with BRCA-mutated HER2-negative metastatic breast cancer. Using the random-effect model, we calculated summary risk estimates (pooled HR and OR with 95% CI) for progression-free survival (PFS), overall survival (OS), objective response rate (ORR), any grade and grade 3-4 adverse events (AEs), treatment discontinuation rate and time to deterioration in quality of life (QoL). Two RCTs (n=733) were included. As compared with monochemotherapy, single-agent PARPi significantly ...
Triple-negative breast cancer (TNBC) which is defined by the lack of expression of estrogen receptor (ER) and progesterone receptor (PR) and absence of human epidermal growth factor receptor type 2 (H
Additional file 1: Figure S1. of Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells
PRIMARY OBJECTIVES:. I. To determine the recommended phase II dose of veliparib along with carboplatin on a 14-day and 21-day schedule in patients with Her2 negative metastatic breast cancer that are estrogen receptor (ER)/progesterone receptor(PR) negative or ER and/or PR positive with defects in Fanconi Anemia (FA) pathway repair genes.. II. To determine the safety and tolerability of combining veliparib on a 14-day and 21-day schedule with carboplatin in this patient population.. III. To determine the preliminary efficacy of this combination in this patient population.. SECONDARY OBJECTIVES:. I. To determine the pharmacodynamic endpoints of poly(ADP-ribose) polymerase (PARP) inhibition in the tumor by using, A) 3-[F-18]fluoro-3-deoxythymidine positron emission tomography (FLT-PET) of the target lesions, B) circulating tumor cells to detect the induction of the histone variant gamma H2AX, and C) peripheral blood mononuclear cells to assess poly ADP-Ribose (PAR) levels.. II. To determine ...
Clinical benefit rate (CR, PR, or SD = 24 weeks) for women For ErbB2 Positive Advanced Breast Cancer. Clinical benefit rate was the percentage of subjects who achieved overall tumor response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), ,=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.. Clinical Benefit (CB) = CR + PR + SD ,= 24 weeks. ...
CancerConnect News: In patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer, the combination of Herceptin® (trastuzumab) plus a taxane resulted in delayed time to cancer progression and was associated with fewer side effects than Tykerb® (lapatinib) plus a taxane, according to final clinical trial results reported in the Journal of Clinical Oncology. The HER2 pathway is a biological pathway involved in cellular replication and growth. Approximately 20-25% of breast cancers overexpress the HER2 protein and are referred to as HER2-positive. Herceptin and Tykerb both target and block the HER2-protein, and are used for the treatment of both early-stage and more advanced HER2-positive breast cancer.. The NCIC Clinical Trials Group enrolled and evaluated 537 patients in 21 countries with centrally confirmed HER2-postive advanced breast cancer that were treated with a taxane plus Tykerb or Herceptin. These individuals have now been followed a median of 21.5 ...
With the increasing availability of agents that target individual ErbB receptors, the possible combinations incorporating these agents are numerous. This discussion will be limited to combinations employing trastuzumab and EGFR tyrosine kinase inhibitors in the treatment of HER-2-positive breast cancer. HER-2-positive metastatic breast cancer may be the best setting in which to test the concurrent inhibition of multiple ErbB receptors, because the pathogenesis and progression of the disease are driven by amplification of the HER-2/neu gene, and breast cancer patients can be selected for targeted therapy based on the presence of this molecular abnormality. Trastuzumab, the prototypical ErbB-targeted therapy, has a single agent response rate of 34% in women with metastatic HER-2/neu-positive breast cancer as measured by fluorescence in situ hybridization (47). Preclinical experiments have shown that trastuzumab has synergistic activity when combined with chemotherapeutic agents such as ...
Erlotinib is a Human Epidermal Growth Factor Receptor Type 1/Epidermal Growth Factor Receptor (HER1/EGFR) tyrosine kinase inhibitor. It is marketed as Tarceva for the treatment of locally advanced or metastatic non-small cell lung cancer or pancreatic cancer.
We are at the beginning of Personalized Medicine. This concept can take many forms. It can mean an evaluation the DNA of a breast cancer that predicts a poor prognosis. (Overexpression of the human epidermal growth factor receptor type 2, HER2) It can also mean a diagnostic test to determine if a patient will response to a specific type of cancer treatment like Gleevec (imatinib). Recently, several companies have started offering over the counter DNA tests. These are presently being evaluated by the FDA because of concerns for consistently and how they will be interpreted ...
Treatment of human epidermal growth factor receptor 2 (HER2)-driven breast cancer with the HER-targeting tyrosine kinase inhibitor lapatinib can lead to a rapid compensatory increase in expression, signaling activity and relocalization of HER3 to the plasma membrane, which may attenuate the response to lapatinib. This might imply a potential role for a more dynamic assessment of HER3 tumor status using molecular imaging techniques, such as positron emission tomography (PET), instead of immunohistochemical HER3 staining on tumor biopsies. Here, we explored the feasibility of a dynamic assessment of HER3 status during lapatinib treatment in human breast cancer xenografts using zirconium-89 labeled anti-human HER3 monoclonal antibody (mAb) as a potential tracer for animal PET imaging.. The anti-human HER3 mouse mAb MAB3481 was used for all experiments. The effect of lapatinib treatment on HER3 expression and HER3 mAb internalization in human breast cancer cell lines SKBR3 and BT474 was determined ...
These studies in a rat model of LM human breast cancer demonstrated that regional IT therapy with MAb 4D5, directed against the HER2/neu receptor, inhibits growth of HER2/neu overexpressing xenografts. Metastatic breast cancer lesions outside of the CNS respond to therapy with i.v. anti-HER2/neu antibody (9 , 10) , but MAbs administered i.v. do not cross the blood-brain barrier and cannot be detected in the CSF or in LM tumor tissue (26 , 27) . A recently completed clinical trial using chemotherapy plus anti-HER2/neu antibody to treat metastatic breast cancer that overexpresses HER2 (10) found that in patients with progressive disease, the CNS was the only site of disease progression in 23 of 153 (15%) of those treated with chemotherapy plus antibody compared with 16 of 200 (8%) of those treated with chemotherapy alone. In the current study, continuous IVent infusion produced therapeutic concentrations of the antibody in the CSF and resulted in antibody attachment to LM human breast cancer ...
Introduction: Despite improvements in treatment with newly approved HER2-targeted therapies, safe and effective treatments are still needed, not only for HER2-positive metastatic breast cancer (MBC), but also for MBC expressing intermediate levels of HER2 that are still considered HER2-negative (e.g. IHC 2+, FISH-negative). MM-302 is a liposomal antibody drug conjugate (ADC) designed to target doxorubicin to HER2-overexpressing cancer cells. MM-302 is currently being evaluated in HER2-positive locally advanced breast cancer (LABC)/MBC patients in the registration-directed HERMIONE trial. The objective of this study was to compare the relative efficacy of MM-302 and PLD in treating HER2-intermediate MBC (corresponding to 1+/2+ by IHC) using models that closely mimic how HER2-overexpressing metastatic tumors are established in humans.. Methods: To establish metastatic disease, the murine 4T1-HER2 cell line engineered to express intermediate levels of Her2 (median of ∼1×105 HER2 receptors/cell), ...
Trastuzumab is by far the drug of choice for treatment of human epidermal growth factor receptor 2 (Her2) overexpressing breast cancer patients. However, frequently, the therapy remains ineffective...
Health,Researchers Edith Perez and Edward Romond reported from two separate trials that Breast cancer patients with Her2-positive were effectively treated with Herceptin therapy using trastuzumab. //The results of their study were published in the journal The New England Journal of Medicine. The researchers compiled results from two clinical trials which compared patients getting only chemotherapy with,Trastuzumab,therapy,effective,for,Breast,cancer,patients,with,Her-2/neu,positive,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
Doxorubicin has been an integral part of the treatment of women with breast cancer for many years. Since amrubicin may have more activity than doxorubic
The discovery of Human Epidermal growth factor Receptor 2 (HER2) positive breast cancer subtypes is not yet complete, according to Mark D. Pegram, MD, who will be delivering a presentation on the different clinical outcomes of these subtypes at the Miami Breast Cancer Conference this week.
Sigma-Aldrich offers Sigma-E5900, Monoclonal Anti-c-erbB-4 antibody produced in mouse for your research needs. Find product specific information including CAS, MSDS, protocols and references.
OBJECTIVES: Brain metastases (BM) are a significant complication of metastatic breast cancer (MBC). The high incidence of BM in HER2 overexpressing MBC is now well recognized, however, the optimal management of such patients is not yet clearly defined. We aimed to analyze factors affecting survival after diagnosis of BM in patients treated in our center. MATERIALS AND METHODS: Retrospective analysis of survival in all patients treated with antineoplastic therapy for BM from MBC in our institution between May 1st 2002 and April 30th 2005, according to HER2 expression and use of trastuzumab after diagnosis of BM. RESULTS: The median survival of the 26 patients with HER2 overexpressing disease after diagnosis of BM was significantly longer than that of the 60 patients with HER2 nonoverexpressing disease (6.2 vs. 3.8 months, P = 0.027). Further analysis revealed that this seems to be due to the favorable outcome of the 70% (n = 18) of HER2 overexpressing patients who received trastuzumab after BM were
Background: Testing for human epidermal growth factor receptor-2 (HER-2) is routinely performed after breast cancer diagnosis by either immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH). FISH is more accurate and reproducible, often considered the gold standard, and a more reliable predictor of a patients response to HER-2 directed therapies in clinical practice. The growth factor receptor-bound protein-7 gene (GRB7) encodes a multi-domain signal transduction molecule located in close proximity to HER-2 on chromo some 17q11-12 and has been shown to be an independent adverse prognostic marker in breast cancer. Methods: We performed western blotting analysis of protein extracts from 563 annotated frozen breast tumors, collected from 1988 - 1998. GRB7 and HER-2 bands were assigned low or high values compared to specific protein controls, and tubulin bands. HER-2 FISH was performed on a subset of these tumors using an FDA approved Path Vysion kit on 4 μm frozen sections. ...
Methods for the detection, monitoring and treatment of malignancies in which the HER-2/neu oncogene is associated are disclosed. Detection of specific T cell activation (e.g., by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2/neu protein, or detection of immunocomplexes formed between the HER-2/neu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2/neu oncogene is associated. The present invention also discloses methods and compositions, including peptides, for treating such malignancies.
1. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, Leahy DJ. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003;421:756-760 2. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U. et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230:1132-1139 3. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39-51 4. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;27:1323-1333 5. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med. 2008;358:1409-1411 6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival ...
|p|erbB-2|strong| |/strong|is a transmembrane, tyrosine kinase (TK) receptor whose overexpression is associated with adverse prognosis in breast cancer|sup|1|/sup|.|/p| |p|The human epidermal growth factor receptor (erbB-2) is a transmembrane receptor th
Approximately a quarter of women with HER2 positive breast cancer, who were treated with a combination of the targeted drugs lapatinib and trastuzumab before surgery and chemotherapy, saw their tumours shrink significantly or even disappear, according to results from a clinical trial. The University of Manchesters Professor Nigel Bundred tol...
Purpose: SRC-family kinases (SFK) are involved in numerous oncogenic signaling pathways. A phase 2 trial of dasatinib, a potent oral tyrosine kinase inhibitor of SFKs, was carried out in patients with human epidermal growth factor receptor 2-positive (HER2+) and/or hormone receptor-positive (HR+) advanced breast cancer.. Experimental Design: Patients with measurable tumors and progression after chemotherapy and HER2 and/or HR-targeted agents in adjuvant or metastatic settings (maximum of two prior metastatic setting regimens) received twice daily dasatinib. Primary endpoint was Response Evaluation Criteria in Solid Tumors-defined response rate. Secondary endpoints included toxicity and limited pharmacokinetics.. Results: Seventy patients (55 years median age) were treated, 83% of HER2+ patients had received prior HER2-directed therapy, and 61% of HR+ patients had received prior endocrine therapy in the advanced setting. Dasatinib starting dose was reduced from 100 to 70 mg twice daily to limit ...
Background: Abemaciclib is an oral selective inhibitor of cyclin-dependent kinases 4 and 6 approved for hormone receptor (HR)+, human epidermal growth factor receptor 2 (HER2)- metastatic breast cancer. In the randomized, 3-arm, phase 2 study monarcHER (NCT02675231) for HR+, HER2+ advanced breast cancer (ABC), abemaciclib in combination with trastuzumab (T) and fulvestrant (F) significantly improved investigator-assessed progression-free survival (whereas abemaciclib + T did not) versus (vs) T + physicians choice of chemotherapy and demonstrated a tolerable safety profile. Here, patient-reported HRQoL, functioning, and symptoms are reported. Methods: In monarcHER, 237 postmenopausal (surgical, natural, or chemical ovarian suppression) women with ABC and ?2 prior HER2+ directed therapies in the advanced setting were randomized 1:1:1 to abemaciclib (150 mg PO Q12H every 21 days) + T (IV infusion on D1 every 21 days) with F (500 mg IM on Cycle 1 D1 and D15 and Cycle 2 D8, then Q4W; Arm A) or ...
Prof Piccart: Dr Fatima Cardoso gave a beautiful summary of 15 years of clinical experience with trastuzumab. She started with the management of advanced HER2-positive breast cancer. Please remember that because it is an aggressive disease, it is not so uncommon that patients present with advanced HER2-positive disease at diagnosis. So she first reminded us that you can find a discordance between the HER status of the primary tumour and the HER status of the recurrent tumour. There have been many publications on this theme and there has been a recent meta-analysis and, to make a long story short, you can expect this type of discordance in about 10% of the patients. And so what should you do when this happens? There was a consensus emerging from the advanced breast cancer conference a year and a half year ago where the experts felt that if this happens you should give the patient the targeted drug anyway; so if the tumour was HER2-negative initially and it becomes HER2-positive you should try an ...
Recombinant human ErbB 4 protein Protein fragment datasheet (ab85602). Abcam offers quality products including antibodies, assays and other reagents.
Buy our Recombinant Human ErbB 4 protein. Ab61640 is a protein fragment produced in Insect cells and has been validated in FuncS, SDS-PAGE. Abcam provides free…
Women with HER2-positive breast cancer had an improved rate of complete tumor disappearance in just 12 weeks when the monoclonal antibody pertuzumab was added to standard therapy.
M.BELIMEZI, B. FILIPPI, K. VOURVOUHAKI, A. MAMALAKI). The oncoprotein HER2/neu (c-erbB-2) is a member of the erbB receptor family with tyrosine kinase activity. It is the principal component of the heterodimers that are formed among members of the erbB family (EGFR, erbB-3, erbB-4) in the presence of growth factors, which result in the activation of those signaling pathways that lead to cell proliferation and differentiation. Any alteration in the tightly regulated signaling cascade of HER-2/neu cause severe abnormalities and carcinogenesis. HER2/neu is overexpressed in approximately 30% of human breast and ovarian cancer, and has been associated with aggressiveness and poor prognosis. In addition, HER2/neu has been shown to be overexpressed, in a large number of other human malignancies including ovarian, colon, lung, prostate and cervical cancers. HER2/neu overexpression in neoplasmatic cells activates the immune system, as it is detected from the increased title of antibodies against HER2/neu ...
Abnormal expression and signaling of the ErbB receptors is associated with the development and progression of several forms of cancer. In this thesis, new ErbB-targeting affibody molecules are evaluated regarding their cellular effects in vitro. Since ligand binding to an ErbB receptor might have an impact on the cell it is important to be aware of these effects as they may have consequences for the continued growth of the tumor when used in vivo. The affibody molecules are intended for tumor targeting with the prospect of clinical use in imaging or therapy.. Three types of affibody molecules were studied, HER2-binding, EGFR-binding and bispecific binders that target both EGFR and HER2. The HER2-targeting (ZHER2:342)2 showed promising characteristics. It sensitized SKBR-3 cells to irradiation and decreased cell growth to the same extent as the clinically approved antibody Herceptin. The monomeric version, ZHER2:342, did not induce any large effects on intracellular signaling or biological ...
in European Journal of Cancer (2007), 43(4), 725-35. AIM: Trastuzumab (T), a humanised monoclonal antibody against HER-2, is active in HER-2-positive MBC patients. However, nearly 60% of the patients do not benefit from T, stressing the need for additional ... [more ▼]. AIM: Trastuzumab (T), a humanised monoclonal antibody against HER-2, is active in HER-2-positive MBC patients. However, nearly 60% of the patients do not benefit from T, stressing the need for additional predictive markers. The following markers could be implicated in response to T: (1) the magnitude of Her-2 gene amplification; (2) the co-expression of the other HER family receptors, possibly responsible for HER-2 trans-activation; (3) the activated status of HER-2; (4) the activated status of downstream effectors as mitogen-activated protein kinases (MAPKs), p38 and p27. METHODS: Medical files of patients with MBC treated with T either as a single agent or in combination with chemotherapy (CT) were reviewed. HER family ...
There are several genetic profiles of IBC. My cancer is estrogen and progesterone negative and her2/neu positive. The HER2neu marker is apparently what proteins feed the cancer. Since I am Her2neu+, I can take an infused drug called Herceptin every three weeks and my cancer just starves to death and is quite incapacitated. Then there is Tykerb, which I dabble in from time to time. Tykerb comes in pill form and attacks stray cancer cells in a different way than Herceptin. The biggest point of departure is that the drug molecules are smaller so they permeate the barrier between the brain and the body, thus protecting ones old noggin from nastiness. Herceptin doesnt provide much of a kick. Yeah, a crummy headache for awhile and a distinct sense of doom with respect to my tennis game for the first day or so. Tykerb makes you feel oh so young again--with acne to remind you of your youth. And for some strange reason, skin just doesnt like it in general. It seems to put all the oil onto your ...
Yes. I do not like that fact, but that is what the research shows. Remember that this a a median, which means half live longer than that. There is lots of research now on metastatic TNBC--it is what absolutely needs and deserves the focus now. We need a targeted therapy for metastatic TNBC, and that is what researchers are looking for. Lets pray they find it soon. It has been amazing to see how one drug, Herceptin, changed the prognosis of Her2-positive breast cancer from being dismal to being rosy. Lets hope we have that drug for TNBC soon. ...
There is an emerging theme in HER2-positive breast cancer: The greater the pathway inhibition, the better the outcome. The latest evidence comes from the phase III Clinical Evaluation of Pertuzumab and Trastuzumab (CLEOPATRA) trial of 808 patients with previously untreated metastatic disease. The.... ...
ErbB 4兔单克隆抗体[E200](ab32375)可与小鼠, 大鼠, 人样本反应并经WB, IP, IHC, ICC, Flow Cyt实验严格验证,被11篇文献引用并得到1个独立的用户反馈。
ウサギ・ポリクローナル抗体 ab15140 交差種: Hu 適用: WB,IHC-P…ErbB 4抗体一覧…画像、プロトコール、文献などWeb上の情報が満載のアブカムの Antibody 製品。国内在庫と品質保証制度も充実。
TY - JOUR. T1 - Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer. T2 - Results of the randomized phase II CHER-LOB study. AU - Guarneri, Valentina. AU - Frassoldati, Antonio. AU - Bottini, Alberto. AU - Cagossi, Katia. AU - Bisagni, Giancarlo. AU - Sarti, Samanta. AU - Ravaioli, Alberto. AU - Cavanna, Luigi. AU - Giardina, Giovanni. AU - Musolino, Antonino. AU - Untch, Michael. AU - Orlando, Laura. AU - Artioli, Fabrizio. AU - Boni, Corrado. AU - Generali, Daniele Giulio. AU - Serra, Patrizia. AU - Bagnalasta, Michela. AU - Marini, Luca. AU - Piacentini, Federico. AU - DAmico, Roberto. AU - Conte, PierFranco. PY - 2012/6/1. Y1 - 2012/6/1. N2 - Purpose: This is a noncomparative, randomized, phase II trial of preoperative taxane-anthracycline in combination with trastuzumab, lapatinib, or combined trastuzumab plus lapatinib in patients with human epidermal growth factor receptor 2 (HER2) -positive, stage II ...
TY - JOUR. T1 - Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy. AU - Lipton, Allan. AU - Leitzel, Kim. AU - Ali, Suhail M.. AU - Carney, Walter. AU - Platek, Greg. AU - Steplewski, Klaudia. AU - Westlund, Ron. AU - Gagnon, Robert. AU - Martin, Anne Marie. AU - Maltzman, Julie. PY - 2011/11/1. Y1 - 2011/11/1. N2 - BACKGROUND: Changes in serum human epidermal growth factor receptor 2 (HER2) levels associated with clinical outcomes, including objective response rate, progression-free survival (PFS), and overall survival have been reported in patients with metastatic breast cancer (MBC) receiving trastuzumab and chemotherapy. This study investigated whether baseline or changes in serum HER2 correlated with overall response rate (ORR) and/or PFS in patients with MBC receiving first-line lapatinib monotherapy. METHODS: The EGF20009 study ...
TY - JOUR. T1 - Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. AU - Carey,Lisa A.. AU - Berry,Donald A.. AU - Cirrincione,Constance T.. AU - Barry,William T.. AU - Pitcher,Brandelyn N.. AU - Harris,Lyndsay N.. AU - Ollila,David W.. AU - Krop,Ian E.. AU - Henry,Norah Lynn. AU - Weckstein,Douglas J.. AU - Anders,Carey K.. AU - Singh,Baljit. AU - Hoadley,Katherine A.. AU - Iglesia,Michael. AU - Cheang,Maggie Chon U.. AU - Perou,Charles M.. AU - Winer,Eric P.. AU - Hudis,Clifford A.. PY - 2016/2/20. Y1 - 2016/2/20. N2 - Purpose Dual human epidermal growth factor receptor 2 (HER2) targeting can increase pathologic complete response rates (PCRs) to neoadjuvant therapy and improve progression-free survival in metastatic disease. CALGB 40601 examined the impact of dual HER2 blockade consisting of trastuzumab and lapatinib added to paclitaxel, ...
Breast cancer is a heterogeneous disease encompassing a number of phenotypically diverse tumours. Expression levels of the oestrogen, progesterone and HER2/neu receptors which characterize clinically distinct breast tumours have been shown to change during disease progression and in response to systemic therapies. Mi(cro)RNAs play critical roles in diverse biological processes and are aberrantly expressed in several human neoplasms including breast cancer, where they function as regulators of tumour behaviour and progression. The aims of this study were to identify miRNA signatures that accurately predict the oestrogen receptor (ER), progesterone receptor (PR) and HER2/neu receptor status of breast cancer patients to provide insight into the regulation of breast cancer phenotypes and progression. Expression profiling of 453 miRNAs was performed in 29 early-stage breast cancer specimens. miRNA signatures associated with ER, PR and HER2/neu status were generated using artificial neural networks (ANN), and
CancerConnect News: The CDK4/6 inhibitor Kisqali (ribociclib) has been given breakthrough status by the US Food and Drug Administration as an initial endocrine-based treatment for of pre- or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in combination with tamoxifen or an aromatase inhibitor.. Results from the Phase III MONALEESA-7 trial evaluating Kisqali® in combination endocrine-based therapy in premenopausal or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer are the basis for the breakthrough status designation.1. About Kisqali® Kisqali is a selective cyclin-dependent kinase inhibitor-this class of drugs helps slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow ...
Looking for online definition of c-erb B2/neu protein in the Medical Dictionary? c-erb B2/neu protein explanation free. What is c-erb B2/neu protein? Meaning of c-erb B2/neu protein medical term. What does c-erb B2/neu protein mean?
BACKGROUND: The mechanisms of resistance to anti-human epidermal growth factor receptor 2 (HER 2) therapies are unclear but may include the tyrosine-protein kinase Met (c-Met), vascular endothelial growth factor (VEGF) and AXL pathways. Foretinib is an inhibitor of c-Met, VEGF receptor 2 (VEGFR-2), platelet-derived growth factor receptor beta (PDGFRB), AXL, Fms-like tyrosine kinase 3 (FLT3), angiopoiten receptor (TIE-2), RET and RON kinases. This phase Ib study sought to establish the associated toxicities, pharmacokinetics (PK) and recommended phase II doses (RP2D) of foretinib and lapatinib in a cohort of HER-2-positive patients with metastatic breast cancer (MBC). METHODS: Women with HER-2 positive MBC, Performance status (PS 0-2), and no limit on number of prior chemotherapies or lines of anti-HER-2 therapies were enrolled. A 3 + 3 dose escalation design was utilized. Four dose levels were intended with starting doses of foretinib 30 mg and lapatinib 750 mg orally once a day (OD) on a ...
Background: Development of a multidrug resistance (MDR) phenotype to chemotherapy remains a major barrier in the treatment of cancer. Gankyrin (p28, p28GANK or PSMD10) is an oncoprotein overexpressed in different carcinoma cell lines. The aim of this study was to compare Gankyrin expression level in MDR cells (MCF-7/ADR and MCF-7/ MX) and non-MDR counterparts (MCF-7). Methods: Gankyrin, MDR1 (also known as ABCB1; the ATP-binding cassette sub-family B member 1) and ABCG2 (also known as BCRP; the human breast cancer resistance protein) mRNA levels were analyzed by real-time RT-PCR. Western blot analysis was used to detect the protein expression levels of Gankyrin. Results: The PCR results showed that the expression of Gankyrin was significantly lower in the ABCG2 overexpressing cell line MCF-7/MX than in non-resistanct MCF-7 cells. In contrast, there were no significant differences in mRNA expression of Gankyrin in the MDR1 overexpressing cell line MCF-7/ADR in comparison with MCF-7 cells. Similarly,
A new study has revealed that a combination of chemotherapy and treatment with two drugs lengthens survival of patients with HER2-positive metastatic breast cancer.